These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35929665)

  • 1. Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches.
    Paul S; Nadendla S; Sobhia ME
    J Phys Chem Lett; 2022 Aug; 13(32):7420-7428. PubMed ID: 35929665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.
    Patil S; Alzahrani KJ; Banjer HJ; Halawani IF; Alzahrani H; Altayar MA; Albogami S; Angeles RF; Hassan AAA; Bhandi S; Raj AT
    J Infect Public Health; 2022 Jul; 15(7):781-787. PubMed ID: 35738053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors.
    Sarma S; Herrera SM; Xiao X; Hudalla GA; Hall CK
    J Phys Chem B; 2022 Oct; 126(41):8129-8139. PubMed ID: 36219223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron Binding Mode: Contact Analysis and Dynamics of the Omicron Receptor-Binding Domain in Complex with ACE2.
    Fazekas Z; Menyhárd DK; Perczel A
    J Chem Inf Model; 2022 Aug; 62(16):3844-3853. PubMed ID: 35849759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analysis of spike protein of SARS-CoV-2 (Omicron variant) for development of peptide-based therapeutics and diagnostics.
    Pritam M; Dutta S; Medicherla KM; Kumar R; Singh SP
    J Biomol Struct Dyn; 2024 Sep; 42(14):7321-7339. PubMed ID: 37498146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants.
    Sang P; Chen YQ; Liu MT; Wang YT; Yue T; Li Y; Yin YR; Yang LQ
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring conformational landscapes and binding mechanisms of convergent evolution for the SARS-CoV-2 spike Omicron variant complexes with the ACE2 receptor using AlphaFold2-based structural ensembles and molecular dynamics simulations.
    Raisinghani N; Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
    Phys Chem Chem Phys; 2024 Jun; 26(25):17720-17744. PubMed ID: 38869513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study.
    Aksenova AY; Likhachev IV; Grishin SY; Galzitskaya OV
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant.
    Bayani F; Safaei Hashkavaei N; Uversky VN; Mozaffari-Jovin S; Sefidbakht Y
    Comput Biol Med; 2022 Aug; 147():105735. PubMed ID: 35767919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the transmission feasibility of SARS-CoV-2 Omicron (B.1.1.529) variant to 143 mammalian hosts: insights from S protein RBD and host ACE2 interaction studies.
    Samanta A; Alam SSM; Ali S; Hoque M
    Funct Integr Genomics; 2023 Jan; 23(1):36. PubMed ID: 36631570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
    Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
    J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
    Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
    Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An
    Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
    J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.